Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Evaluation of a novel inhibitor of aspartate semialdehyde dehydrogenase as a potent antitubercular agent against Mycobacterium tuberculosis

The Journal of Antibiotics volume 75, pages 333–340 (2022)Cite this article

Subjects

Abstract

The in vitro activity of IMB-XMA0038, a novel inhibitor targeting Mycobacterial tuberculosis (Mtb) aspartate semialdehyde dehydrogenase, was evaluated. Minimum inhibitory concentrations (MICs) of IMB-XMA0038 were against 20 Mtb isolates, including H37Rv (ATCC 27294), ten clinical pan-sensitive isolates, and nine clinical multidrug-resistant (MDR) isolates. In addition, minimum bactericidal concentrations (MBCs) were also determined against the H37Rv and 6 MDR isolates (the background information is same as above in order). A model was generated to evaluate IMB-XMA0038 activity against dormant Mtb. The post-antibiotic effect (PAE), an important indicator of antimicrobial drug dosing schedules to obtain efficacy, was determined based on time required for regrowth of Mtb to 50% of the OD600max value after treatment with various concentrations of IMB-XMA0038 and INH. In addition, interactions between IMB-XMA0038 and other anti-tuberculosis drugs, measured using a checkerboard assay, revealed that IMB-XMA0038 MICs of 0.5–1 μg/mL could be achieved in combinations. Synergistic effects were observed for IMB-XMA0038 when used together with almost all other anti-tuberculosis drugs against most Mtb isolates. IMB-XMA0038 exhibited greater activity than rifampin against Mtb under hypoxic conditions, as reflected by CFU decreases of 1.1-log-unit versus 0.8-log-unit, respectively, for IMB-XMA0038 and rifampin concentrations of 4 × MIC. IMB-XMA0038-induced PAEs (9, 10, 11 days) were comparable to INH PAEs (10, 11, 12 days). These findings suggest that addition of IMB-XMA0038 to current therapeutic regimens could be useful to improve the efficacy of treatments for drug-resistant and drug-susceptible TB.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol. 2020;128:1547–67.

    Article  CAS  Google Scholar 

  2. Verma SK, Verma R, Verma S, Vaishnav Y, Tiwari SP, Rakesh KP. Anti-tuberculosis activity and its structure-activity relationship (SAR) studies of oxadiazole derivatives: A key review. Eur J Med Chem. 2021;209:112886.

    Article  CAS  Google Scholar 

  3. Zuma NH, Smit FJ, Seldon R, Aucamp J, Jordaan A, Warner DF. et al. Single-step synthesis and in vitro anti-mycobacterial activity of novel nitrofurantoin analogues. Bioorg Chem. 2020;96:103587

    Article  Google Scholar 

  4. Suliman S, Pelzer PT, Shaku M, Rozot V, Mendelsohn SC. Meeting report: virtual global forum on tuberculosis vaccines, 20–22 April 2021. Vaccine, 2021;39:7223–9.

    Article  CAS  Google Scholar 

  5. Liu Y, Zhou S, Deng Q, Li X, Meng J, Guan Y. et al. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis. Tuberculosis. 2016;97:38–46.

    Article  CAS  Google Scholar 

  6. Bahuguna A, Rawat DS. An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev. 2020;40:263–92.

    Article  Google Scholar 

  7. Chavan RR, Hosamani KM. Microwave-assisted synthesis, computational studies and antibacterial/ anti-inflammatory activities of compounds based on coumarin-pyrazole hybrid. R Soc Open Sci. 2018;5:172435.

    Article  Google Scholar 

  8. Usha V, Lloyd AJ, Lovering AL, Besra GS. Structure and function of Mycobacterium tuberculosis meso-diaminopimelic acid (DAP) biosynthetic enzymes. FEMS Microbiol Lett. 2012;330:10–6.

    Article  CAS  Google Scholar 

  9. Viola RE, Faehnle CR, Blanco J, Moore RA, Liu X, Arachea BT. et al. The catalytic machinery of a key enzyme in amino Acid biosynthesis. J Amino Acids. 2011;2011:352538

    Article  Google Scholar 

  10. Azevedo RA, Lancien M, Lea PJ. The aspartic acid metabolic pathway, an exciting and essential pathway in plants. Amino Acids. 2006;30:143–62.

    Article  CAS  Google Scholar 

  11. Cirillo JD, Weisbrod TR, Pascopella L, Bloom BR, Jacobs WR Jr. Isolation and characterization of the aspartokinase and aspartate semialdehyde dehydrogenase operon from mycobacteria. Mol Microbiol. 1994;11:629–39.

    Article  CAS  Google Scholar 

  12. Vyas R, Tewari R, Weiss MS, Karthikeyan S. Structures of ternary complexes of aspartate-semialdehyde dehydrogenase (Rv3708c) from Mycobacterium tuberculosis H37Rv. Acta Crystallogr D Biol Crystallogr. 2012;68:671–9.

    Article  CAS  Google Scholar 

  13. Kumar R, Garg P, Bharatam PV. Pharmacoinformatics analysis to identify inhibitors of Mtb-ASADH. J Biomol Struct Dyn. 2016;34:1–14.

    Article  CAS  Google Scholar 

  14. Wang X, Yang R, Liu S, Guan Y, Xiao C, Li C. et al. IMB-XMA0038, a new inhibitor targeting aspartate-semialdehyde dehydrogenase of Mycobacterium tuberculosis. Emerg Microbes Infect. 2021;10:2291–9.

    Article  CAS  Google Scholar 

  15. Leechawengwongs M, Prammananan T, Jaitrong S, Billamas P, Makhao N, Thamnongdee N, et al. In vitro activity and MIC of sitafloxacin against multidrug-resistant and extensively drug-resistant mycobacterium tuberculosis isolated in Thailand. Antimicrob Agents Chemother. 2018;62:e00825–17.

  16. Martini MC, Zhang T, Williams JT, Abramovitch RB, Weathers PJ, Shell SS. Artemisia annua and Artemisia afra extracts exhibit strong bactericidal activity against Mycobacterium tuberculosis. J Ethnopharmacol. 2020;262:113191.

    Article  CAS  Google Scholar 

  17. Sun Q, Wang S, Liao X, Jiang G, Huang H, Li H, et al. Fidaxomicin has high in vitro activity against Mycobacterium tuberculosis. J Med Microbiol. 2021;70:001324.

  18. Coban AY, Akbal AU, Uzun M, Cayci YT, Birinci A, Durupinar B. Evaluation of crystal violet decolorization assay for minimal inhibitory concentration detection of primary antituberculosis drugs against Mycobacterium tuberculosis isolates. Mem Inst Oswaldo Cruz. 2016;111:454–9.

  19. Hussain A, Rather MA, Bhat ZS, Majeed A, Maqbool M, Shah AM. et al. In vitro evaluation of dinactin, a potent microbial metabolite against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2019;53:49–53.

    Article  CAS  Google Scholar 

  20. Jadaun GP, Agarwal C, Sharma H, Ahmed Z, Upadhyay P, Faujdar J. et al. Determination of ethambutol MICs for Mycobacterium tuberculosis and Mycobacterium avium isolates by resazurin microtitre assay. J Antimicrob Chemother. 2007;60:152–5.

    Article  CAS  Google Scholar 

  21. Joung DK, Choi SH, Kang OH, Kim SB, Mun SH, Seo YS. et al. Synergistic effects of oxyresveratrol in conjunction with antibiotics against methicillin-resistant Staphylococcus aureus. Mol Med Rep. 2015;12:663–7.

    Article  CAS  Google Scholar 

  22. Santos NCS, Scodro RBL, Leal DC, do Prado SM, Micheletti DF, Sampiron EG. et al. Determination of minimum bactericidal concentration, in single or combination drugs, against Mycobacterium tuberculosis. Future Microbiol. 2020;15:107–14.

    Article  CAS  Google Scholar 

  23. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol. 2002;43:717–31.

    Article  CAS  Google Scholar 

  24. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996;64:2062–9.

    Article  CAS  Google Scholar 

  25. Hurdle JG, Lee RB, Budha NR, Carson EI, Qi J, Scherman MS. et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother. 2008;62:1037–45.

    Article  CAS  Google Scholar 

  26. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother. 2012;56:5782–9.

    Article  CAS  Google Scholar 

  27. Birteksoz-Tan AS, Zeybek Z. Postantibiotic effect of various antibiotics on Legionella pneumophila strains isolated from water systems. Folia Microbiol. 2012;57:495–9.

    Article  Google Scholar 

  28. Hasenoehrl EJ, Rae Sajorda D, Berney-Meyer L, Johnson S, Tufariello JM, Fuhrer T. et al. Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection. Nat Commun. 2019;10:4215

    Article  Google Scholar 

  29. Cox H, Shah NS, Castro KG. Discovering a new drug is only the beginning: progress and challenges in expanding access to BDQ for MDR-TB treatment. Int J Tuberc Lung Dis. 2020;24:985–6.

    Article  CAS  Google Scholar 

  30. Tato M, López Y, Morosini MI, Moreno-Bofarull A, Garcia-Alonso F, Gargallo-Viola D. et al. Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values. Diagn Microbiol Infect Dis. 2014;78:263–7.

    Article  CAS  Google Scholar 

  31. Cele ZED, Somboro AM, Amoako DG, Ndlandla LF, Balogun MO. Fluorinated quaternary chitosan derivatives: synthesis, characterization, antibacterial activity, and killing kinetics. ACS Omega. 2020;5:29657–66.

    Article  CAS  Google Scholar 

  32. Peterson EJR, Abidi AA, Arrieta-Ortiz ML, Aguilar B, Yurkovich JT, Kaur A. et al. Intricate genetic programs controlling dormancy in mycobacterium tuberculosis. Cell Rep. 2020;31:107577

    Article  CAS  Google Scholar 

  33. Fogel N. Tuberculosis: a disease without boundaries. Tuberculosis. 2015;95:527–31.

    Article  Google Scholar 

  34. Esmail H, Barry CE 3rd, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Disco Today. 2012;17:514–21.

    Article  Google Scholar 

  35. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5:e10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Khan MT, Kaushik AC, Bhatti AI, Zhang YJ, Zhang S, Wei AJ, et al. Marine natural products and drug resistance in latent tuberculosis. Mar Drugs. 2019;17:549.

  37. Banerjee U, Sankar S, Singh A, Chandra N. A multi-pronged computational pipeline for prioritizing drug target strategies for latent tuberculosis. Front Chem. 2020;8:593497.

    Article  CAS  Google Scholar 

  38. Doğan ŞD, Gündüz MG, Doğan H, Krishna VS, Lherbet C, Sriram D. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors. Eur J Med Chem. 2020;199:112402.

    Article  Google Scholar 

  39. Chandramohan Y, Padmanaban V, Bethunaickan R, Tripathy S, Swaminathan S, Ranganathan UD. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. J Glob Antimicrob Resist. 2019;19:348–53.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the study coordinators and staff at the hospital for their contributions to this research. This study was supported by Natural Sciences Foundation of China (NSFC, Grant No. 81803412), and the Beijing Key Clinical Specialty Project.

Author information

Authors and Affiliations

  1. Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University / Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China

    Ruifang Yang, Qiao Li, Chen Liang, Weicong Ren, Yi Liu & Chuanyou Li

  2. Department of Respiratory and Critical Care Medicine, Beijing Geriatric Hospital, Beijing, 100095, China

    Wenli Cao

  3. Department of Tuberculosis, Anhui Chest Hospital, Hefei, Anhui, 230022, China

    Shengsheng Liu

  4. Department of Clinical Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China

    Yong Sun

  5. Institute of Medical Biotechnology, Chinese Academy of Medical Sciences, Beijing, 100050, China

    Jianzhou Meng

Authors
  1. Ruifang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenli Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shengsheng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chen Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weicong Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jianzhou Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chuanyou Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jianzhou Meng or Chuanyou Li.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, R., Cao, W., Liu, S. et al. Evaluation of a novel inhibitor of aspartate semialdehyde dehydrogenase as a potent antitubercular agent against Mycobacterium tuberculosis. J Antibiot 75, 333–340 (2022). https://doi.org/10.1038/s41429-022-00520-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41429-022-00520-y

Search

Advanced search

Quick links